| COVID-19 papers n = 54 | Non COVID papers n = 114 |
---|---|---|
Method, n (%) | ||
 Randomised controlled trial | 6 (11%) | 60 (53%) |
 Observational | 46 (85%) | 37 (32%) |
 Systematic reviews | 1 (2%) | 11 (10%) |
 Test accuracy | 0 (0%) | 4 (4%) |
 Other | 1 (2%) | 2 (2%) |
Content median (IQR) | ||
 Total number included | 96 (16.5 to 762) | 815 (219 to 4893)* |
 Follow-up (weeks) | 4 (3 to 7) | 52 (28 to 116)* |
 Positive result, n (%) | 7 (13%) | 74 (65%)* |
 Industry funding, n (%) | 2 (4%) | 31 (27%)* |
Post-publication, n (%) | ||
 Brief report format | 16 (30%) | 6 (5%)* |
 Editorial | 31 (57%) | 43 (38%)** |
 Correction/retraction | 7 (13%) | 0 (0%)* |